Fifth Anniversary Episode: Five Years Later... Where and How to Legally Access Psychedelic Medicines

In this episode of the Psychedelic Medicine Podcast, podcast host Dr. Lynn Marie Morski comes on the mic to provide a five-year update on the podcast and share the changes in the legal landscape of psychedelics in the past half-decade. Lynn Marie Morski, MD, JD is the president of the Psychedelic Medicine Association and host of the Psychedelic Medicine Podcast. She sits on the advisory boards of Psychedelics Today, Cybin, VETS, Inc (Veterans Exploring Treatment Solutions), the Oxenberg Foundation, and the Ketamine Task Force. Dr. Morski is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor.

In this anniversary episode you'll hear about the legally-accessible forms of psychedelic therapy which have come to prominence as potential mainstream therapeutics in recent years. Dr. Mroski shares Information on the legal adult use framework for psilocybin in Oregon, including licensing, costs, and exclusion criteria. She also discusses programs in Australia and Canada that will allow certain patients to access psychedelic therapies such as psilocybin- and MDMA-assisted therapy. In addition to classic psychedelic medicines, Dr. Morski also shares information on the medicine which is currently most accessible: ketamine. She discusses the difference between S-ketamine and R-ketamine and on-label and off-label uses of this substance. In closing, Dr. Morski presents some of the finer details of the current landscape of insurance coverage for ketamine.

In this episode you'll hear:

• The difference between decriminalization and legalization
• The FDA decision to deny the Lykos Therapeutics' new drug application for MDMA-assisted therapy for PTSD
• The upcoming Colorado psilocybin program
• Psychiatric licenses to administer MDMA and LSD to patients in Australia
• The Special Access Program for psychedelic therapies in Canada
• Legal ketamine access in the United States
• How the Psychedelic Medicine Podcast chooses guests

Quotes:

"I wanted to focus mostly on what is legal because we know that's the way things are going to be the most monitored and therefore safely accessible." [20:45]

"People are in this industry because they want other people to feel better and they want to help and they're so generous with their time" [25:31]

Links:

clinicaltrials.gov - the place to find information on upcoming clinical trials for psychedelic medicine for which you may qualify

Insurance Coverage for Psychedelic Therapy by Vincent Joralemon

SPRAVATO withMe Patient Support Program

Enthea insurance

Previous episode: How to Choose A Psychedelic Facilitator or Retreat Center with Joël Brierre

Previous episode: Warning Signs When Selecting a Psychedelic Facilitator with Juliana Mulligan

Previous episode: Ketamine Scientific Research with Dr. Jason Wallach

Psychedelic Medicine Association

Porangui